Class I glucose-6-phosphate dehydrogenase deficiency
glue-kohs-six-fos-fate dee-hy-droh-juh-nays dih-fish-en-see
Also known as: G6PD deficiency, Class I, Severe G6PD deficiency
At a Glance
What is Class I glucose-6-phosphate dehydrogenase deficiency?
Class I glucose-6-phosphate dehydrogenase deficiency is a rare genetic disorder that affects the body's ability to process glucose properly. It primarily impacts the red blood cells, leading to their premature destruction. This condition is caused by mutations in the G6PD gene, which is responsible for producing an enzyme that protects red blood cells from damage. Over time, individuals with this deficiency may experience chronic hemolytic anemia, which can worsen during infections or exposure to certain medications. Early symptoms often include fatigue, jaundice, and dark urine, while later symptoms can involve more severe anemia and related complications. Early diagnosis is crucial to manage symptoms effectively and prevent severe episodes. The condition can significantly impact family life, as it requires constant vigilance to avoid triggers. Prognosis varies, but with proper management, individuals can lead relatively normal lives. Daily life involves avoiding certain foods and medications that can trigger hemolysis. Regular medical check-ups are essential to monitor the condition. Education and awareness are key for both the patient and their family. Support from healthcare professionals and patient communities can greatly aid in managing the disorder.
Medical Definition
Class I glucose-6-phosphate dehydrogenase deficiency is a severe form of G6PD deficiency characterized by chronic non-spherocytic hemolytic anemia. Pathologically, it involves the inability of red blood cells to maintain their integrity due to oxidative stress. Histologically, affected red blood cells may show signs of Heinz bodies and increased hemolysis. It is classified under the G6PD deficiency variants, with Class I being the most severe. Epidemiologically, it is rare, with a higher prevalence in certain ethnic groups, particularly those of Mediterranean, African, and Asian descent. The disease course involves chronic anemia with potential acute hemolytic episodes triggered by infections, certain drugs, or foods.
Class I glucose-6-phosphate dehydrogenase deficiency Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Hemolytic anemia manifests as fatigue, pallor, and shortness of breath due to the rapid destruction of red blood cells. The biological mechanism involves the deficiency of glucose-6-phosphate dehydrogenase, which leads to oxidative damage and premature breakdown of red blood cells. Over time, this condition can lead to chronic anemia if not managed properly. It affects daily life by causing persistent fatigue and reduced exercise tolerance, and management includes avoiding triggers and sometimes blood transfusions.
Jaundice presents as yellowing of the skin and eyes, resulting from elevated bilirubin levels due to excessive breakdown of red blood cells. The underlying mechanism is the liver's inability to process the increased bilirubin load caused by hemolysis. If persistent, jaundice can lead to complications such as kernicterus in severe cases. Daily life can be impacted by the need for regular monitoring and potential treatments like phototherapy in severe cases.
Dark urine occurs due to the presence of excess bilirubin and hemoglobin breakdown products in the urine. This symptom is a direct result of increased hemolysis and the kidneys filtering out these byproducts. Over time, dark urine can indicate ongoing hemolysis and the need for medical intervention. Patients may need to increase fluid intake and avoid known triggers to manage this symptom effectively.
Common
Fatigue is a common symptom characterized by persistent tiredness and lack of energy. It is caused by the reduced oxygen-carrying capacity of the blood due to anemia. Over time, fatigue can worsen if anemia is not treated, leading to decreased quality of life. Management includes addressing the underlying anemia and ensuring adequate rest and nutrition.
Pallor is the noticeable paleness of the skin and mucous membranes, often seen in anemic patients. It results from reduced blood flow and decreased hemoglobin levels in the blood. Pallor can become more pronounced with worsening anemia and may indicate the need for medical evaluation. It can affect self-esteem and social interactions, and treatment involves managing the anemia.
Shortness of breath is a sensation of difficulty breathing, often exacerbated by physical exertion. It is caused by the reduced oxygen delivery to tissues due to anemia. Over time, this symptom can limit physical activity and lead to a sedentary lifestyle. Management includes treating the underlying anemia and engaging in gentle, supervised exercise.
Less Common
Splenomegaly is the enlargement of the spleen, which can occur due to increased red blood cell destruction. The spleen becomes overactive in filtering damaged cells, leading to its enlargement. Over time, splenomegaly can cause abdominal discomfort and increase the risk of spleen rupture. Management may involve regular monitoring and, in severe cases, splenectomy.
Gallstones can form as a result of increased bilirubin production from hemolysis. The excess bilirubin can precipitate in the gallbladder, forming stones. Over time, gallstones can lead to biliary colic and complications like cholecystitis. Management includes dietary modifications and, if necessary, surgical removal of the gallbladder.
What Causes Class I glucose-6-phosphate dehydrogenase deficiency?
Class I glucose-6-phosphate dehydrogenase deficiency is caused by mutations in the G6PD gene, located on the X chromosome at position Xq28. The G6PD gene encodes the enzyme glucose-6-phosphate dehydrogenase, which is crucial for the pentose phosphate pathway, a metabolic pathway that generates NADPH. NADPH is essential for protecting cells from oxidative damage by maintaining the levels of reduced glutathione. Specific mutations in the G6PD gene can lead to structural changes in the enzyme, reducing its stability or activity. This disruption results in decreased NADPH production, impairing the cell's ability to counteract oxidative stress. Red blood cells, which rely heavily on this pathway for protection against oxidative damage, are particularly affected. The deficiency leads to hemolysis, or the breakdown of red blood cells, causing anemia and related symptoms. In severe cases, the lack of NADPH can also affect other tissues, leading to broader systemic effects. The immune response may be activated due to the release of cellular contents from lysed cells, contributing to inflammation. Neuroinflammation is not typically a primary feature, but systemic inflammation can have indirect effects on the nervous system. The degeneration of white matter is not a direct consequence of this deficiency, but chronic oxidative stress can impact various cellular structures. Symptoms often appear during oxidative stress episodes, such as infections or exposure to certain drugs or foods. The severity of the disease varies between patients due to the specific mutation present and the degree of enzyme activity retained.
How is Class I glucose-6-phosphate dehydrogenase deficiency Diagnosed?
Typical age of diagnosis: Class I glucose-6-phosphate dehydrogenase deficiency is typically diagnosed in early childhood, often following an episode of acute hemolytic anemia triggered by infection or exposure to certain medications or foods.
The clinician looks for signs of hemolytic anemia, such as jaundice, pallor, and fatigue. A detailed history is taken to identify any recent infections, medication use, or ingestion of fava beans. Physical examination may reveal splenomegaly or hepatomegaly. This step helps to determine the likelihood of a hemolytic disorder and guides further diagnostic testing.
Ultrasound of the abdomen is often used to assess the size of the spleen and liver. Imaging may reveal splenomegaly, which is consistent with hemolytic anemia. These findings support the diagnosis but are not specific to glucose-6-phosphate dehydrogenase deficiency. Imaging helps exclude other causes of abdominal pain and jaundice, such as gallstones or liver disease.
A complete blood count (CBC) and reticulocyte count are ordered to assess anemia and bone marrow response. Low hemoglobin and elevated reticulocytes suggest hemolytic anemia. A direct antiglobulin test (Coombs test) is negative, ruling out autoimmune hemolytic anemia. Enzyme assays show reduced G6PD activity, confirming the deficiency.
Sequencing of the G6PD gene is performed to identify specific mutations. Common mutations include G6PD A- and G6PD Mediterranean. Identification of these mutations confirms the diagnosis and helps predict the severity of the deficiency. Genetic results are crucial for family counseling and assessing the risk in relatives.
Class I glucose-6-phosphate dehydrogenase deficiency Treatment Options
Folic acid is a vitamin supplement used to support red blood cell production. It works by aiding in the synthesis of nucleic acids, which are essential for erythropoiesis. Folic acid is commonly prescribed to prevent folate deficiency due to increased red blood cell turnover. Clinical evidence supports its use in managing chronic hemolysis. Side effects are rare but can include gastrointestinal discomfort.
Techniques include pacing activities and prioritizing tasks to manage fatigue. The goal is to improve daily functioning and quality of life. Sessions are typically conducted weekly and adjusted based on patient progress. Outcomes are measured by improved energy levels and reduced fatigue. Long-term benefits include enhanced ability to perform daily activities and reduced risk of overexertion.
Indicated for patients with severe, recurrent hemolytic episodes unresponsive to other treatments. The procedure involves surgical removal of the spleen. Benefits include reduced hemolysis and improved hemoglobin levels. Risks include increased susceptibility to infections and surgical complications. Post-operative care includes vaccinations and prophylactic antibiotics.
The care team includes hematologists, nutritionists, and social workers. Interventions focus on managing anemia, dietary counseling, and psychosocial support. Strategies include stress management and coping skills for patients and families. Education covers avoiding triggers and recognizing early signs of hemolysis. Long-term monitoring involves regular follow-ups and laboratory assessments.
When to See a Doctor for Class I glucose-6-phosphate dehydrogenase deficiency
- Severe jaundice — this indicates a rapid breakdown of red blood cells and requires immediate medical intervention.
- Dark-colored urine — this can signify acute hemolysis, which is a medical emergency.
- Sudden onset of fatigue or weakness — this may indicate severe anemia, necessitating urgent care.
- Pallor or paleness — this could suggest anemia and should prompt a visit to the doctor for evaluation.
- Frequent infections — this may indicate compromised immunity and requires medical assessment.
- Persistent headache — this could be a sign of anemia-related complications and should be discussed with a healthcare provider.
- Mild fatigue — monitor energy levels and ensure adequate rest and nutrition.
- Occasional dizziness — keep track of occurrences and consult a doctor if it worsens.
Class I glucose-6-phosphate dehydrogenase deficiency — Frequently Asked Questions
Is this condition hereditary?
Class I glucose-6-phosphate dehydrogenase deficiency is inherited in an X-linked recessive pattern. This means males are more frequently affected, while females can be carriers. De novo mutations are rare but possible. Female carriers have a 50% chance of passing the mutated gene to their sons. Genetic counseling is recommended to understand carrier status and reproductive options.
What is the life expectancy for someone with this condition?
Life expectancy can be normal with proper management, especially if diagnosed early. Factors such as avoiding triggers and managing infections improve outcomes. Severe hemolytic episodes can lead to complications that may reduce life expectancy. Treatment, including transfusions and medications, can significantly enhance survival. Realistic expectations involve regular medical follow-ups and lifestyle adjustments.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves a combination of clinical evaluation and laboratory tests, including enzyme assays. The time from first symptoms to diagnosis can vary, often taking weeks to months. Hematologists and geneticists are typically consulted. Delayed diagnosis may occur due to non-specific symptoms and lack of awareness. Confirmation is achieved through genetic testing or enzyme activity measurement.
Are there any new treatments or clinical trials available?
Research is ongoing, with gene therapy being a promising area. Novel approaches like enzyme replacement therapy are under investigation. Clinical trials can be found on ClinicalTrials.gov by searching for G6PD deficiency. Discussing potential trials with your doctor is crucial for understanding eligibility and risks. New treatments may become available in the next few years, but timelines are uncertain.
How does this condition affect daily life and activities?
The condition can impact mobility and self-care during hemolytic episodes. Educational adjustments may be necessary due to fatigue or frequent absences. Social and emotional challenges include coping with chronic illness and potential stigma. Family burden involves managing healthcare needs and lifestyle adaptations. Supportive measures like counseling and educational support can significantly improve quality of life.
Support & Resources
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-04-26